2019
DOI: 10.1200/jco.2019.37.15_suppl.2528
|View full text |Cite
|
Sign up to set email alerts
|

Ramucirumab (Ram) and durvalumab (Durva) treatment of metastatic non-small cell lung cancer (NSCLC), gastric/gastroesophageal junction (G/GEJ) adenocarcinoma, and hepatocellular carcinoma (HCC) following progression on systemic treatment(s).

Abstract: 2528 Background: A Phase 1b study (NCT02572687) was conducted to examine the combined effects of Ram (anti VEGFR2) and Durva (anti PD-L1). Methods: Patients (pts) with previously-treated, advanced NSCLC (Cohort [CH] A), G/GEJ adenocarcinoma (CH B), HCC (CH C), ECOG PS 0-1, and no prior Ram or IO therapy, received Ram (10 mg/kg) + Durva (1125 mg) Q3W (CH A) or Ram (8 mg/kg) + Durva (750 mg) Q2W (CH B, C). Primary objective was to assess safety; efficacy was also examined. PD-L1 expression of tumor cells (TC) +… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
20
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 25 publications
(20 citation statements)
references
References 0 publications
0
20
0
Order By: Relevance
“…7,21,22 Most of the recently reported early-phase trials of anti-PD-1/anti-PD-L1 plus antiangiogenic agents for advanced HCC were initially parts of basket trials testing the same regimen in multiple cancer types. [23][24][25][26][27] The HCC cohorts were selected for further development because of the promising antitumor activity demonstrated by these regimens, with ORRs of 10-50% and median PFS of more than 6 months ( Table 1). It was recently announced that the combination of atezolizumab and bevacizumab demonstrated superior OS and PFS compared to sorafenib in the first-line treatment of advanced HCC 158 .…”
Section: Promising Data On Immuno-oncology Combinations For Advanced Hccmentioning
confidence: 99%
See 1 more Smart Citation
“…7,21,22 Most of the recently reported early-phase trials of anti-PD-1/anti-PD-L1 plus antiangiogenic agents for advanced HCC were initially parts of basket trials testing the same regimen in multiple cancer types. [23][24][25][26][27] The HCC cohorts were selected for further development because of the promising antitumor activity demonstrated by these regimens, with ORRs of 10-50% and median PFS of more than 6 months ( Table 1). It was recently announced that the combination of atezolizumab and bevacizumab demonstrated superior OS and PFS compared to sorafenib in the first-line treatment of advanced HCC 158 .…”
Section: Promising Data On Immuno-oncology Combinations For Advanced Hccmentioning
confidence: 99%
“…113,114 The impact of liver cirrhosis and Child-Pugh score are worthy of extensive investigation in HCC, as results from early-phase clinical trials implied that patients with HCC may have increased liver-related adverse events, compared with other cancer types, when treated with ICI-based combinations. 26 Although steroids are the mainstay of irAE treatment, their impact on the efficacy of ICI therapy and their role in irAE prevention remain controversial. 115,116 Firstly, most of these studies indicate that treatment of irAEs with steroids or other immunomodulatory agents may not affect ICI treatment response.…”
Section: Optimal Management Of Immune-related Adverse Eventsmentioning
confidence: 99%
“…Co-targeting the PD-(L)1 and VEGF signaling axes is the most extensively studied combination approach for advanced HCC (188,189). Results from single-arm studies showed that combinations of VEGF and PD-(L)1 inhibitors were associated with a manageable safety profile and promising antitumor activity, with ORRs of 11% to 50% (190)(191)(192)(193)(194)(195).…”
Section: Hepatocellular Carcinomamentioning
confidence: 99%
“…For example, the Phase III IMpower150 trial provided evidence that the efficacy of atezolizumab is augmented by the anti-VEGF agent bevacizumab, when these two agents are combined with chemotherapy for first-line treatment of EGFR-mutant non-squamous NSCLC [24]. Phase I studies have also shown activity of ramucirumab plus either pembrolizumab or durvalumab in previously treated advanced NSCLC [31,32], and nivolumab plus bevacizumab as maintenance therapy for non-squamous NSCLC following first-line chemotherapy [33].…”
Section: Tablementioning
confidence: 99%